Of these patients, 46 patients were excluded because they had limited-stage SCLC, and 36 patients were excluded because they were lost to follow-up after the first dose of PD-1/PD-L1 treatment without subsequent image review. This evidence concerns the gene PDCD1 and small cell lung carcinoma.